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Since its discovery in 1922, insulin has been thought to be required for normal metabolic
homeostasis and survival. However, this view would need to be revised as recent
results from different laboratories have convincingly indicated that life without insulin is
possible in rodent models. These data indicate that particular neuronal circuitries, which
include hypothalamic leptin-responsive neurons, are empowered with the capability of
permitting life in complete absence of insulin. Here, we review the neuronal and peripheral
mechanisms by which leptin signaling in the central nervous system (CNS) regulates
glucose metabolism in an insulin-independent manner.
Keywords: leptin, leptin receptors, insulin, diabetes mellitus, diabetes mellitus type 1, diabetes mellitus type 2,
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Introduction
The concept that “living without insulin is possible” may sound senseless as insulin signaling
has long been thought to be essential for normal development and coordinated metabolic pro-
cesses (e.g., glucose and lipid handling) in several species (e.g., from worms to humans) (Kenyon,
2010). However, recent findings indicate that insulin is dispensable for normal glucose and lipid
metabolism as leptin monotherapy rescues glucose and lipid metabolic aberrancies and lethality
caused by insulin deficiency, at least, in adult rodents (Yu et al., 2008; Fujikawa et al., 2010, 2013;
Wang et al., 2010; Lee et al., 2012a). These results are interesting as we may be able to exploit the
mechanisms underlying leptin’s anti-diabetic action to develop better strategies against diabetes
(Fujikawa et al., 2010, 2013). Since the very beginning, leptin has been shown to regulate glucose
metabolism independently to its food-intake-suppressing action (Pelleymounter et al., 1995). Nev-
ertheless, we suspect that no one could have imagined that leptin can regulate glucose metabolism
in an insulin-independent manner at that time. Shortly after, researchers began realizing that lep-
tin’s effects on glucose metabolismmight be separated into an insulin-dependent and -independent
manner (Haque et al., 1999; Shimomura et al., 1999; Yaspelkis et al., 1999; Hidaka et al., 2002). Also,
several scientific evidences indicate that themajority (if not all) of the glucose-lowering effect of lep-
tin arises from its action on hypothalamic neurons (Coppari et al., 2005; Huo et al., 2009; Berglund
et al., 2012). Yet, the concrete evidence supporting that leptin signaling in the CNS can regulate
glucose homeostasis independently of insulin emerged only very recently.
Nobody seriously examined the possibility that “living without insulin is possible” until Dr.
Roger Unger and his colleagues at University of Texas Southwestern Medical School in Dal-
las (USA) set out to tackle this possibility. They found that systemic overexpression of leptin
ameliorates hyperglycemia in a near-complete insulin-deficient mouse model (Yu et al., 2008).
Next, we revealed that the CNS is key to regulate glucose homeostasis in response to leptin in
a similar insulin-deficient mouse model (Fujikawa et al., 2010). Furthermore, we demonstrated
that intracerebroventricular (i.c.v.) leptin administration ameliorates hyperglycemia in complete
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insulin-deficient mice bearing a genetically-engineered gene that
allows ablation of almost 100% of pancreatic β-cells; a degree of
β-cells deficiency that is not achievable with any other animal
model to date (Fujikawa et al., 2013).
Thus, almost 100 years after insulin was discovered, we
now realize that mammalian organisms are equipped with
neuro-circuities that can be exploited to restore normal glucose
metabolism in the insulin-deficient setting. Yet, the exact com-
ponents of this remarkable circuit have yet to be fully identified.
One important issue need however to be considered. Because
the amount of leptin needed to achieve virtually normal glu-
cose and lipid metabolism in the absence of insulin is supra-
physiological (Wang et al., 2010), it is very likely that these
CNS circuitries have little physiological meaning. Nevertheless,
identification of the underling mechanisms represents a unique
opportunity to unmask molecular components which can then
eventually become effective targets for better anti-diabetic drugs.
Firstly, leptin therapy itself is unlikely to be effective in improving
diabetes in humans because of the known leptin-resistant char-
acteristic of these subjects (Myers et al., 2012). Secondly, because
insulin is not required it is plausible that harnessing these molec-
ular mechanisms could represent an ideal avenue to improve
both types of diabetes; the insulin-deficient type 1 (T1DM) and
the insulin-resistant type 2 diabetes mellitus (T2DM). Obvi-
ously, major efforts aimed at identifying these new putative
anti-diabetes target(s) are currently underway.
In this review, we discuss the mechanism by which leptin sig-
naling in the CNS regulates glucose metabolism in the absence of
insulin.
Leptin Regulates Glucose Metabolism in
Insulin-Dependent and -Independent
Manner
In 1994, leptin was found by Friedman and colleagues who used
positional cloning method to identify the mutation causing mas-
sive obesity in ob/ob mice (Zhang et al., 1994). A year later, lep-
tin receptors (LEPRs) were also identified (Tartaglia et al., 1995;
Chen et al., 1996). Leptin is expressed primary in adipose tis-
sues (Zhang et al., 1994) and LEPRs are intensively expressed in
the CNS (Gautron and Elmquist, 2011), although LEPRs expres-
sion is found in peripheral tissues as well (Margetic et al., 2002;
Muoio and Lynis Dohm, 2002). In 1995, it was already known
that leptin administration at a dose that does not affect body
weight and food intake can restore normoglycemia in otherwise
hyperglycemic ob/ob mice (Pelleymounter et al., 1995), suggest-
ing indeed an important and direct role of leptin in coordi-
nating glucose metabolism. Originally, leptin action on glucose
metabolism appeared to be mediated by its insulin sensitizing
effects (Schwartz et al., 1996; Barzilai et al., 1997). For exam-
ple, systemic leptin administration dramatically reduces glu-
cose levels along with insulin levels in otherwise hyperglycemic
and hyperinsulinemic ob/ob mice (Schwartz et al., 1996). Lep-
tin administration increases peripheral glucose uptake during
insulin clamp (Barzilai et al., 1997), which support the notion that
leptin is an insulin-sensitizer cue.
Kamohara and colleagues firstly pointed out the possibil-
ity that leptin’s action on glucose metabolism may be classi-
fied into in an insulin-dependent and -independent manner
(Kamohara et al., 1997). They found that either systemic (intra-
venous) or i.c.v. leptin administration increases glucose uptake
in skeletal muscle and brown adipose tissue (BAT). Although
their report did not provide concrete evidence, authors specu-
lated that the glucoregulatory action of leptin might be executed
independently of insulin (Kamohara et al., 1997). Chinookos-
wong and colleagues demonstrated that systemic leptin adminis-
tration restores normoglycemia in otherwise hyperglycemic rats
with low circulating insulin levels (∼70 pg/mL) (Chinookoswong
et al., 1999). Hidaka and colleagues found that leptin injection
into the third cerebral ventricle also improves hyperglycemia
in a similar animal model (Hidaka et al., 2002). Hence, collec-
tively these results suggested that leptin exerts glycemia-lowering
action by sensitizing metabolically relevant tissues to insulin but
also in an insulin-independent manner.
There is no doubt that the aforementioned studies represent
milestones in the process of recognizing the ability of leptin sig-
naling in the CNS to ameliorate hyperglycemia in animal models
of hypoinsulinemia. However, because insulin was still present
(albeit at low levels) these studies were not able to address the
crucial question whether insulin is required for the anti-diabetic
action of leptin (Shimomura et al., 1999). In fact, it is possible that
leptin signaling in the brain can hypersensitize peripheral tissues
to insulin in a way that even low level of insulin is sufficient to
maintain normal glucose levels in the blood in these otherwise
diabetic animals.
In the following years researchers continued to use this
hypoinsulinemic rodent model, but Unger and colleagues re-
highlighted the action of leptin on glucose metabolism by gen-
erating and testing leptin’s anti-diabetic action in near-complete
insulin-deficient mice. They used a high-dose streptozotocin
(STZ)-based approach to ablate the vast majority of pancreatic β-
cells. STZ is a chemical that enters cells expressing glucose trans-
porter 2 (GLUT2) and that destroys DNA in those cells (Lenzen,
2008). Using their pharmacological β-cells ablationmodel, Unger
and colleagues generated near complete insulin-deficientmice (in
this model insulin level is below 5 pg/mL, which is the threshold
of detection of the most sensitive ELISA method used to quan-
tify insulin), and demonstrated that systemic overexpression of
leptin alleviates hyperglycemia in these mice (Yu et al., 2008).
Moreover, their preclinical study shows that continuous systemic
leptin administration ameliorates hyperglycemia and that it can
reduce dosage of insulin for anti-diabetic treatment, suggesting
that leptin may be applicable in the clinical setting as an adjuvant
to insulin therapy (Wang et al., 2010).
The action of leptin on glucose metabolism in near complete
insulin-deficient mice is mediated by the CNS (Fujikawa et al.,
2010). In fact, i.c.v. leptin treatment recapitulates virtually all
the metabolic improvements caused by systemic leptin adminis-
tration in near complete insulin-deficient mice (Fujikawa et al.,
2010). Combined with earlier work, these results then suggest
that the CNS is key to leptin’s action on glucose metabolism
in an insulin-independent manner, as well as in the context of
insulin sufficiency (Pelleymounter et al., 1995; Kamohara et al.,
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1997). Although the pharmacological approach used by Unger
and colleagues can bring about virtually undetectable circulat-
ing insulin level, it cannot completely eliminate insulin-positive
cells in the pancreas (Yu et al., 2008; Fujikawa et al., 2010). Thus,
these studies were not able to rule in or out the possibility that
the tiny amount of pancreatic insulin somehow underlies the
anti-diabetic action of i.c.v. leptin administration. To address
this issue we used a genetic tool generated by Thorel et al. They
developed amousemodel bearing diphtheria toxin (DT) receptor
gene driven by the rat-insulin promoter (RIP-DTRmice) (Thorel
et al., 2010). DTR is not expressed in experimental mice (Saito
et al., 2001), thus DT injections only affect and eradicate the cells
expressing DTR. Following DT injections, RIP-DTR mice show
ablation of almost 100% of pancreatic β-cells (Thorel et al., 2010;
Fujikawa et al., 2013). DT-treated RIP-DTR mice exhibit no cir-
culating insulin, and their pancreatic insulin is barely detectable;
this is a degree of β-cell ablation far superior to the one achieved
by STZ injections (Thorel et al., 2010). Of note, i.c.v. leptin treat-
ment reverses hyperglycemia and permits survival of DT-treated
RIP-DTR mice (Fujikawa et al., 2013).
Figure 1 depicts the chronicle of crucial discoveries on lep-
tin’s action on glucose metabolism. Although recurrent obser-
vations demonstrate that leptin signaling in the CNS can reg-
ulate glucose metabolism in insulin-deficient rodents, the neu-
ronal mechanism underlying this action has just started to be
understood.
Diversity of Neuronal Networks Underlying
Leptin’s Action on Glucose Metabolism
The discovery of leptin opened up the door of the genetic era in
the field investigating the mechanism by which the CNS regu-
lates metabolic homeostasis. Since then, researchers have focused
on understanding the molecular mechanism by which the CNS
regulates metabolism. LEPRs are broadly expressed in the brain
including in the hypothalamus and brain stem which are well
known to regulatemetabolism. It is safe to say that the vast major-
ity of the physiological function of leptin is mediated by LEPRs
in the CNS, although LEPRs are expressed in peripheral tissues
as well (Margetic et al., 2002; Muoio and Lynis Dohm, 2002). A
large number of studies have unraveled the mechanism under-
lying leptin’s action on food intake and body weight regulation
(Gautron and Elmquist, 2011; Coppari and Bjorbaek, 2012), how-
ever the precise mechanism underlying leptin’s action on glucose
metabolism in the context of insulin-intact and -deficient models
are still largely unknown.
Within the CNS, the hypothalamus is a key region for the reg-
ulation of glucose metabolism by leptin. Minokoshi et al. showed
that microinjection of leptin into the ventromedial hypotha-
lamic nuclei (VMH) of rats recapitulates the effect of i.c.v.
leptin administration on glucose uptake in peripheral tissues
(Minokoshi et al., 1999). In 2005, we reported that direct action
of leptin on LEPRs in the hypothalamic arcuate nucleus (ARC),
which is located in the ventral region of the hypothalamus, is
sufficient to restore normoglycemia in otherwise hyperglycemic
LEPRs null mice (Coppari et al., 2005). Huo et al. demonstrated
that over-expression of LEPR-b, which is a biological isoform of
LEPRs, in all proopiomelanocortin (POMC) neurons is sufficient
to achieve similar glucose improvements in otherwise LEPRs null
mice (Huo et al., 2009). Given that the leptin-responsive neurons
appear to be∼30% of POMCneurons in the ARC (Williams et al.,
2010) and the over-expression of LEPR-b under cytomegalovirus
promoter forces LEPRs to be expressed at super-physiological
levels in all POMC neurons, the physiological role of leptin-
responsive POMC neurons was still unclear at that time. Later,
Berglund et al. found that reactivation of endogenous LEPRs
only in POMC neurons is sufficient to restore normoglycemia
in otherwise hyperglycemic LEPRs null mice; this glucose effect
was seen, despite no changes in body weight and food intake
(Berglund et al., 2012). Reactivation of LEPRs only in POMC
neurons restores insulin sensitivity in the liver and suppresses
hyperglucagonemia in mice otherwise displaying severe hep-
atic insulin resistance and elevated level of circulating glucagon
(Berglund et al., 2012). Other studies have shown the importance
of POMC neurons on glucose metabolism (Kievit et al., 2006;
Parton et al., 2007; Hill et al., 2009, 2010).
Similarly to other biological systems, LEPRs network in the
CNS likely is a redundant system. This seems to be particularly
true for its effect on body weight (Balthasar et al., 2004; Dhillon
et al., 2006; van de Wall et al., 2008; Hill et al., 2010; Leinninger
et al., 2011; Vong et al., 2011; Leshan et al., 2012; Dodd et al.,
2014), and may be on glucose metabolism as well. Agouti-related
peptide (AgRP) is expressed in the juxtaposed-neurons to POMC
neurons in the ARC and 10-20% of AgRP neurons are leptin-
responsive neurons (Mizuno and Mobbs, 1999; Wilson et al.,
1999). Recently, Goncalves et al. found that over-expression of
LEPR-b in all AgRP neurons of rescues hyperglycemia in other-
wise LEPRs null mice and deletion of LEPRs only in AgRP neu-
rons diminishes leptin’s glucose lowering effects in the context of
T2DM (Goncalves et al., 2014). Again, only 10–20% of AgRP neu-
rons express LEPR-b (Wilson et al., 1999), thus the physiological
function of endogenous LEPRs in AgRP neurons is still undeter-
mined. Nonetheless, LEPRs in AgRP neurons may play a key role
in the regulation of glucosemetabolism as well as POMCneurons
do. Further studies will be needed to firmly establish the role of
LEPRs in AgRP neurons on glucose homeostasis in the context of
T1DM and T2DM.
The results from studies performed in the context of insulin-
intact rodents indicate that distinct chemically identified neu-
rons, such as POMC neurons, are important for the regulation
of glucose homeostasis. One can imagine that the same neuronal
LEPRs system also mediate anti-diabetic actions of leptin in the
context of complete-insulin deficiency. Surprisingly, our recent
study indicates that this is not the case. LEPRs in POMC neurons
are sufficient to maintain glucose levels, but not required for nor-
mal glucose homeostasis in the context of insulin-intact model.
In fact, reactivation of LEPRs only in POMC neurons is suffi-
cient to ameliorate hyperglycemia in otherwise diabetic LEPRs
null mice (Berglund et al., 2012), while deletion of LEPRs only in
POMC neurons has no effect on blood glucose levels (Balthasar
et al., 2004). Contrary to insulin-intact models, LEPRs in POMC
neurons are not sufficient to restore normoglycemia, but are par-
tially required for leptin’s anti-diabetic actions in the context of
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FIGURE 1 | The timeline of historical findings of leptin’s anti-diabetic actions.
T1DM (Fujikawa et al., 2013). Reactivation of LEPRs only in
POMCneurons is not sufficient for achieving the anti-T1DM and
lifesaving action of leptin administration, and deletion of LEPRs
only in POMC neurons slightly hampers these actions of leptin
(Fujikawa et al., 2013). Notably, despite the importance of LEPRs
in the VMH on the regulation of glucose uptake in peripheral
tissues (Minokoshi et al., 1999), LEPRs in VMH appear to be
not essential for leptin’s anti-T1DM and -T2DM actions. Over-
expression of LEPRs in streroidgenic factor-1 (SF-1) neurons
which are located exclusively in the VMH does not affect glu-
cose levels in otherwise LEPRs null mice, and deletion of LEPRs
in SF-1 neurons has no impact on leptin’s anti-diabetic actions
in the context of insulin-intact models (Goncalves et al., 2014).
Deletion of LEPRs only in SF-1 neurons either does not affect lep-
tin’s anti-diabetic actions in insulin-deficient models (Fujikawa
et al., 2013; Meek et al., 2013). Collectively, the aforementioned
studies suggest that an array of LEPRs-expressing neurons is
required for leptin’s anti-diabetic actions in the absence of insulin
while a single chemically-identified neuronal group is sufficient
for mediating the anti-diabetic action of leptin in the presence of
insulin (Huo et al., 2009; Berglund et al., 2012; Goncalves et al.,
2014).
In general, neurons are classified into either glutamatergic
excitatory or γ-aminobutyric (GABA)-ergic inhibitory neurons,
although recent study suggests that some particular neurons can
produce and release both glutamate andGABA as neurotransmit-
ters (Root et al., 2014). Vong et al. investigated the fundamental
query whether LEPRs in glutamatergic or GABAergic neurons
are important for leptin’s actions on physiological function. To
this end, they generated mice expressing Cre-recombinase only
in glutamatergic or GABAergic neurons which enable to manip-
ulate LEPRs only in those neurons (Vong et al., 2011). Deletion
of LEPRs only in GABAergic neurons leads to massive obesity,
hyperphagia, hyperglycemia and other metabolic defects, which
are of similar (yet not identical) magnitude as the ones seen in
whole-body LEPR null mice (Vong et al., 2011). Contrary to dele-
tion of LEPRs in GABAergic neurons, that only in glutamatergic
neurons causes a slight body weight gain (Vong et al., 2011). The
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study provides the evidence that a distributed rather than a single
neuronal group of LEPRs-expressing neurons plays a crucial role
in leptin’s action on energy balance. This notion is also applied
to the mechanism underlying leptin’s anti-diabetic actions in the
absence of insulin. Reactivation of LEPRs only in GABAergic
neurons is sufficient to mediate anti-diabetic actions of the hor-
mone in the absence of insulin, although the survival rate is not
fully restored (Fujikawa et al., 2013). Leptin administration into
the brain of mice expressing LEPRs only in both GABAergic and
POMC neurons completely restores normoglycemia in otherwise
hyperglycemicmice and permit them to survive at similar degrees
as the ones seen in LEPRs-intact controls (Fujikawa et al., 2013).
These results indicate that leptin’s anti-diabetic actions in the
absence of insulin require a broad neuronal network. Figure 2
depicts the summary of leptin’s diabetic actions in the presence
and absence of insulin.
Within GABAergic neurons, the leptin-responsive GABAergic
neurons are restrictedly located in the hypothalamus, in partic-
ular the ARC, dorsomedial hypothalamic nucleus (DMH), and
lateral hypothalamic area (LHA) (Vianna and Coppari, 2011;
Fujikawa et al., 2013). In the ARC, two neuronal populations
are known as GABAergic neurons. AgRP neurons are almost
100% GABAergic in nature (Vong et al., 2011), and recently RIP-
Cre neurons are identified as ARC GABAergic neurons as well
(Kong et al., 2012). As described above, LEPRs in AgRP neurons
may have a potential to mediate leptin’s anti-diabetic actions in
the absence of insulin (Goncalves et al., 2014). RIP-Cre express-
ing cells are broadly positioned in the CNS and pancreatic β-
cells (Song et al., 2010; Wicksteed et al., 2010). RIP-Cre neurons
are defined as neurons expressing Cre under rat-insulin pro-
moter (ins2), in particular using a mouse strain Tg(Ins2-cre)25Mgn
(Jackson laboratory, stock #003573) or Tg(Ins2-Cre)1Herr (Kong
et al., 2012; Rother et al., 2012). Thus, we here describe RIP-
Cre expressing cells in the CNS as RIP25Mgn-Cre or RIP1Herr-Cre
neurons.
RIP1Herr-Cre neurons show far less Cre-activity in the CNS
compared to RIP25Mgn-Cre neurons (Wicksteed et al., 2010;
Rother et al., 2012), indicating that RIP-Cre neuronsmay not rep-
resent endogenous ins2-expressing cells in the CNS. Nonetheless,
RIP25Mgn-Cre neurons in the ARC are distinguished from AgRP
and POMC neurons (Kong et al., 2012), and are GABAergic in
nature (Kong et al., 2012). Activation of RIP25Mgn-Cre neurons
in the ARC causes thermogenesis (Kong et al., 2012) and it is
well known that thermogenesis accompanies with increases in
glucose uptake in peripheral tissues (Cypess et al., 2009; Virta-
nen et al., 2009; van Marken Lichtenbelt et al., 2009). Moreover,
some of RIP25Mgn-Cre neurons in the ARC are leptin-responsive
neurons (Kong et al., 2012). Thus, it is virtually possible that
the leptin-responsive RIP25Mgn-Cre neurons play a crucial role
in mediating the leptin’s anti-diabetic actions in the absence of
insulin through the thermogenesis-induced glucose uptake. Con-
trary to RIP25Mgn-Cre neurons, it is not clear whether RIP1Herr-
Cre neurons are leptin-responsive. Ablation of RIP1Herr-Cre
neurons dramatically reduces food intake and body weight, but
it does not affect glucose tolerance, indicating that RIP1Herr-Cre
neurons may not regulate glucose homeostasis (Rother et al.,
2012).
LEPRs-expressing neurons in the DMH are known to regulate
thermogenesis through the sympathetic nervous system (SNS)
(Enriori et al., 2011; Dodd et al., 2014; Rezai-Zadeh et al., 2014).
It is not clear whether those DMH neurons are GABAergic neu-
rons. Additionally, it is still unknown whether LEPRs-expressing
neurons in the DMH regulate glucose homeostasis, but again it
is possible that they play a crucial role in leptin’s anti-diabetic
actions via thermogenesis. The chemical identity of GABAer-
gic leptin-responsive DMH neurons is still unknown; however,
several gene candidates have been proposed to characterize this
neuronal group (e.g., prl, Gpr50, Pcsk5, Sulf1, 4930511J11Rik,
Grp, and Rorb) (Lee et al., 2012b; Rezai-Zadeh et al., 2014). The
leptin-responsive neurons in the LHA are GABAergic neurons,
and regulate food intake (Leinninger et al., 2009). The role of the
leptin-responsive neurons in the LHA in the regulation of glu-
cose homeostasis is still unclear; however, they unlikely mediate
leptin’s anti-diabetic actions (Minokoshi et al., 1999; Leinninger
et al., 2009, 2011). Collectively, the leptin-responsive neurons in
the ARC and DMH are strong candidates for mediating leptin’s
anti-diabetic actions in the absence of insulin. Further studies are
required to unravel the role of these neurons in regulating glucose
homeostasis in the presence and absence of insulin.
Downstream Neuronal and Molecular
Pathways of Leptin’s Anti-Diabetic Actions
in the Absence of Insulin
The neuronal substrates that lay downstream to the first-order
LEPRs-expressing neurons underlying leptin’s anti-diabetic
action are largely unknown. This is true in the context of
insulin-resistant and -deficient diabetes. The paraventricu-
lar hypothalamus (PVH) is a great candidate for conveying
information from leptin-responsive neurons to downstream
sites aimed at regulating glucose metabolism. Various neu-
rons in the ARC including POMC, AgRP, RIP25Mgn-Cre and
RIP1Herr-Cre neurons project to the PVH (Schwartz et al.,
2000; Kong et al., 2012; Rother et al., 2012). POMC neurons
release α-melanocyte-stimulating hormones (α-MSH) (Mains
and Eipper, 1976; Cone, 2006), and AgRP neurons release
AgRP (Lu et al., 2003). These neurotransmitters have opposite
effects on the same melanocortin receptors (MCRs), and one
of MCRs isoform, melanocortin receptor 4 (MC4R), is highly
expressed in the PVH (Balthasar et al., 2005). Additionally,
the leptin-responsive neurons in the DMH strongly connect
to the PVH (Elmquist et al., 1998). A microinjection of nora-
drenalin or serotonin agonist into the PVH and a microdialysis
of thyroid hormone in the PVH increase glucose levels in
the blood and those actions are likely mediated by the SNS-
liver axis (Ionescu et al., 1989; Korte et al., 1991; Klieverik
et al., 2009). Moreover, corticotrophin-releasing hormone
(CRH or CRF) causes hyperglycemia via the hypothalamus-
pituitary-adrenal (HPA)-axis (Jamieson et al., 2006). These
notions clearly suggest that the PVH regulates glucose
homeostasis.
Interestingly, a recent study suggests that the suppressing
effect of leptin on overzealous HPA-axis activity caused by insulin
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FIGURE 2 | Proposed neuronal pathway underlying leptin’s
anti-diabetic actions in the presence and absence of insulin. Schematic
depiction of neuronal circuit underlying leptin’s anti-diabetic actions in (A)
insulin-intact and (B) -deficient model. ARC, hypothalamic arcuate nucleus;
DMH, dorsomedial nucleus; VMH, ventromedial hypothalamic nucleus; AgRP,
Agouti-related peptide; POMC, proopiomelanocortin.
deficiency is key for the anti-diabetic actions of leptin (Perry et al.,
2014). Of note, whether leptin signaling in the CNS affects central
and pituitary components of the HPA axis in complete insulin
deficiency is still unknown. Nevertheless, MC4R is potentially a
vital mediator for the suppressing effect of leptin on HPA-axis.
MTII (agonist for MC3R/4R) administration into the brain stim-
ulates HPA-axis and increases glucose levels, and either MC4R
or CRH antagonist can diminish the glucose-elevating effect of
MTII (Lu et al., 2003). Interestingly, MC4R is required for leptin’s
anti-diabetic actions in the context of T2DM (Goncalves et al.,
2014). MC4R in the PVH likely regulates glucose homeostasis as
reactivation of MC4R only in single-minded homolog 1 (SIM1)
neurons, which represents the vast majority of PVH neurons,
dramatically improves glucose homeostasis in otherwise MC4R
null mice (Shah et al., 2014). Collectively, these studies indicate
that leptin signaling in the brain regulates glucose homeostasis
via the leptin-responsive neurons in the ARC and/or DMH and
that these neurons signal to MC4R neurons in the PVH→ CRH
neurons → HPA-axis to suppress hepatic glucose production
(Figure 3).
As mentioned above, the SNS may also be a crucial
downstream component that facilitates leptin’s anti-diabetic
actions in the absence of insulin. Leptin administration into the
brain enhances glucose uptake in the skeletal muscle and BAT,
and resection of nerves to skeletal muscle completely blocks the
action of leptin on glucose uptake (Kamohara et al., 1997), sug-
gesting that leptin signaling in the brain regulates glucose uptake
via the SNS. In the presence of insulin, b-adrenergic receptors are
likely required for the action of leptin on glucose uptake (Haque
et al., 1999), but those receptors are not necessary for leptin’s anti-
diabetic actions in the absence of insulin (Fujikawa et al., 2013).
Injections of α-adrenergic receptors agonist can increase glu-
cose uptake in the heart (Doenst and Taegtmeyer, 1999), indicat-
ing that these receptors may be involved in leptin’s anti-diabetic
actions in the absence of insulin.
The parasympathetic nervous system (PNS), which is another
arm of the autonomic nervous system, may also be involved in
the mechanism underlying leptin’s anti-diabetic actions in the
absence of insulin. Suppressing action of leptin on glucagon
secretion has been suggested to be crucial for leptin’s anti-diabetic
Frontiers in Neuroscience | www.frontiersin.org 6 March 2015 | Volume 9 | Article 108
Fujikawa and Coppari Living without insulin
FIGURE 3 | Proposed mechanism underlying leptin’s
anti-diabetic actions in the absence of insulin. Depiction of
the proposed central pathways and peripheral tissues by which
leptin signaling in the brain exerts anti-diabetic action in the
absence of insulin. ARC, hypothalamic arcuate nucleus; DMH,
dorsomedial nucleus; VMH, ventromedial hypothalamic nucleus;
PVH, paraventricular hypothalamus; AgRP, Agouti-related peptide;
RIP, rat insulin promoter; MC4R, melanocortin receptor 4; CRH,
corticotrophin-releasing hormone; HPA-axis, hypothalamus-pituitary-
adrenal (HPA)-axis.
actions (Yu et al., 2008; Wang et al., 2010; Unger and Cherring-
ton, 2012). Both the SNS and PNS regulate secretion of pancreatic
glucagon. For instance, stimulation of either the SNS or PNS
increases glucagon secretion from pancreatic α-cells (Marliss
et al., 1973; Kaneto et al., 1974; Bloom and Edwards, 1978). The
PNS projections to the pancreas is made of cholinergic neurons
and blocking muscarinic receptors by atropine reduces the basal
levels of glucagon (Bloom et al., 1974). It is completely unknown
whether leptin signaling in the brain can modulate the PNS;
however, it may be possible that inhibitory action of leptin on
glucagon secretion is mediated by the PNS. It is formally possi-
ble that centrally-delivered leptin leaks to the systemic circulation
hence acting on pancreatic α-cells to directly inhibit glucagon
secretion. However, our results indicate that pancreatic α-cells
are devoid of LEPR-b in the presence and even in the absence
of insulin (Fujikawa et al., 2013).
Intriguingly, recent studies have indicated that LEPRs in non-
neuronal cells in the brain are important for mediating leptin’s
physiological function (Fuente-Martin et al., 2012; Balland et al.,
2014; Kim et al., 2014). Astrocytes have a capability of sensing
alternations in energy, iron and pH levels, and may be involved
in coordinated responses aimed at maintaining these parameters
within the normal range (Garcia-Caceres et al., 2013). Fuente-
Martín et al. demonstrated that leptin can modify glutamate
and glucose transporter expression levels as well as glutamate
and glucose uptake in hypothalamic astrocyte (Fuente-Martin
et al., 2012). Moreover, Kim et al. showed that deletion of
LEPRs specifically in astrocyte using a glial fibrillary acidic pro-
tein (GFAP)-Cre mouse line attenuated anorexinergic effect of
leptin and enhanced orexinergic effect of ghrelin (Kim et al.,
2014). Tanycytes that are glia-like cells and line the third ven-
tricle and median eminence (ME) have emerged as a key com-
municator between cerebrospinal fluid and hypothalamic neu-
rons to regulate whole-body metabolism (Bolborea and Dale,
2013). LEPRs on tanycytes in the ME serve as transporter of
leptin from blood to hypothalamic neurons, and high-fat diet
can disrupt leptin signaling in these cells; an effect suggested
to be contributing to leptin resistance seen in this context (Bal-
land et al., 2014). Although none of aforementioned studies show
that LEPRs in astrocytes or tanycytes are involved in the reg-
ulation of glucose metabolism, it is virtually possible that they
can complement the actions of leptin on neurons on metabolic
homeostasis. Future studies will be required to address this
possibility.
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Targeted Peripheral Tissues for the
Leptin’s Anti-Diabetic Actions
Leptin signaling in the brain governs many peripheral tis-
sues with the goal of maintaining glucose homeostasis. One
of these tissues is likely the liver. Insulin deficiency accelerates
gluconeogenesis and glycogenolysis, hence causing exaggerated
hepatic glucose production. Overexpression of LEPRs in the ARC
in LEPRs null rats restores normal hepatic glucose production
(German et al., 2009). Moreover, re-expression of LEPRs only
in POMC neurons is sufficient to restore normal hepatic glucose
production in otherwise over-productive rodents, suggesting that
leptin-responsive POMC neurons regulate hepatic glucose pro-
duction; this effect is likely due to sensitization of insulin action
on hepatocytes (Berglund et al., 2012).
The specific mechanism by which leptin signaling in the
brain regulates hepatic glucose production is still unclear but
there are two pathways that may be involved in mediating lep-
tin’s actions on the liver. One pathway is the PNS as hep-
atic branch vagatomy (resection of vagus nerve projecting to
the liver and other visceral tissues) attenuates leptin’s insulin-
sensitizing action on the liver (German et al., 2009). Another
pathway is the HPA-axis as described above. Leptin adminis-
tration can suppress hyper-activated HPA axis brought on by
STZ-induced insulin reduction, hence reduce corticosterone lev-
els in the blood that otherwise would stimulate gluconeogenesis
(Perry et al., 2014). Part of exaggerated hepatic glucose produc-
tion likely results from hyperglucagonemia induced by insulin
deficiency. Insulin suppresses glucagon secretion from pancre-
atic α-cells and glucagon is one of the most potent hormones
to induce gluconeogenesis (Unger and Cherrington, 2012). Lep-
tin administration into the brain completely suppresses hyper-
glucagonemia in the absence of insulin (Fujikawa et al., 2010,
2013).
Leptin administration into the brain enhances glucose uptake
in skeletal muscle and BAT in the presence of insulin (Kamo-
hara et al., 1997). Evidences suggest that part of these actions
is likely mediated by the VMH (Minokoshi et al., 1999). How-
ever, again, neither re-expression/overexpression nor deletion
of LEPRs only in SF-1 neurons, which represent the VMH,
affects anti-diabetic actions of leptin both in the presence and
absence of insulin (Fujikawa et al., 2013; Goncalves et al., 2014);
thus the importance of LEPRs in the VMH and enhancement
of glucose uptake in those tissues is still unclear. Interestingly,
subcutaneous transplantation of embryonic BAT can amelio-
rate STZ-induced diabetes (Gunawardana and Piston, 2012),
suggesting that BAT may play a key role in the regulation of
glucose metabolism brought on by leptin in the absence of
insulin.
Remarks and Perspective
The last two decades have witnessed tremendous efforts aimed at
understanding the mechanisms underlying leptin’s anti-diabetic
action in the presence or absence of insulin. Results from these
studies raised the possibility of designing completely new ther-
apeutics for the treatment of diabetes and other metabolic dis-
eases. These studies on leptin’s anti-diabetic actions also provide
support to the notion that “living without insulin is possible.”
Because the current knowledge represent a starting point, in
the near future we will need to understand the following: (i)
the biochemical identity of neuronal populations that are cru-
cial for leptin’s anti-diabetic actions in the absence of insulin;
(ii) whether these effects are due to changes in neuronal mem-
brane activities, and/or transcription, and/or neurotransmitter
secretion (Williams et al., 2011). If alternations in neuronal activ-
ity are required for the actions of leptin, we may be able to
achieve normal glucose homeostasis in the absence of insulin,
without leptin, just by changing the biophysical properties of
crucial neurons. If the actions require transcriptional changes
in targeted neurons and we can identify those genes, mod-
ifications in their expression may restore normoglycemia in
the absence of insulin. There is little doubt that by unravel-
ing the mechanism underlying the life-saving action of leptin
therapy we will pave the way for developing better anti-diabetic
approaches.
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